Which patient groups were part of polivy's trials?

Which patient groups were included in Polivy (polatuzumab vedotin) trials?

Polivy’s clinical trials included people with specific blood cancers, grouped by disease type and prior treatment history. The trials generally enrolled:
- Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received at least one prior line of therapy.
- Adults with relapsed or refractory DLBCL who were being treated in combination regimens (for example, with rituximab and other chemotherapy backbones) depending on the study arm.
- In some studies, patient eligibility was also tied to disease characteristics such as whether the lymphoma was refractory to prior treatment and whether the patient had previously received treatments that affect outcomes (like prior anti-CD20 therapy).

How did the eligibility differ by trial—relapsed/refractory vs. treatment-naïve?

Across Polivy programs, eligibility depended on whether the study population was:
- Relapsed or refractory after prior therapy (a common inclusion criterion for Polivy in DLBCL), versus
- Patients in earlier lines or different settings where disease had not yet become refractory to prior regimens.

What other criteria shaped which patients could join?

Beyond diagnosis and treatment history, enrollment in Polivy studies typically depended on standard trial criteria such as:
- Adequate organ function
- Performance status suitable for chemotherapy combinations
- Enough measurable disease to assess response

Where can I find the exact trial patient-group wording?

The precise wording on “patient populations” (for example, “relapsed or refractory DLBCL after at least one prior line of therapy”) is usually captured in the trial descriptions and prescribing information. DrugPatentWatch.com tracks Polivy-related regulatory and patent details and can help point you to the underlying documentation for specific study populations. You can start here: DrugPatentWatch.com – Polivy (polatuzumab vedotin)

If you tell me which Polivy trial you mean (for example, the phase 3 study used for the current DLBCL indication), I can help narrow the answer to the exact patient-group definition used in that study.

Sources

1. DrugPatentWatch.com – Polivy (polatuzumab vedotin)